{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '6.2 Discussion of Study Design', 'As the purpose of the study is to examine how a 4-week regimen with Prontosan solution and', 'Prontosan gel may impact the patient QoL from baseline to the final treatment visit, an', 'open-label, single-arm design was chosen. The Wound-QoL questionnaire was chosen', 'because of its specificity to chronic wounds, its conciseness and ease of patient completion,', \"and its subscales that may provide a look at specific changes in the patient's life. The 4-week\", 'treatment period selected for this study is based on the current wound care approach that', 'suggests if improvements in healing with standard care are not observed in 4 weeks, then a', 'reassessment of the underlying pathology and a consideration for advanced treatments should', 'be undertaken. 3 In addition, in the randomized clinical study comparing Prontosan solution', 'with saline solution in the treatment of chronic leg ulcers, pain control (as measured on a', 'visual analog scale) was statistically significantly better in the Prontosan group than in the', 'saline group (p<0.05) after 4 weeks of treatment. Thus, measureable changes in the patient', 'QoL may be observed over this time period.', 'Using the same questionnaire; standard, single-use, disposable rulers; the same', 'wound-measuring method; identical cameras; and the same photographic guidelines should', 'ensure consistency across sites and over the period of the study. Training the patient and/or', 'the caregiver in the institutional standard of treatment for home treatments and training the', 'patient/caregiver to use the diary to record treatments should encourage compliance and', 'consistency.', '7', 'SELECTION AND WITHDRAWAL OF PATIENTS', '7.1', 'Inclusion Criteria', 'Patients must meet all of the following criteria in order to be included in the study:', '1. Male or female >18 years of age', '2. Either 2 wounds on 1 leg or 1 wound on each leg or only 1 wound. Wound(s) must', 'be located below the knee', '3.', 'At least one wound must have a surface area >5 cm\u00b2 and 50 cm\u00b2 and it must also be', 'present for >4 weeks', '4. Mean global score >1.18 on the Wound-QoL questionnaire (this will be calculated by', 'the electronic data capture [EDC] system at the time of screening to assess eligibility)', '5. Willingness to wear an off-loading device if medically indicated (e.g., DH shoe or', 'walker)', '7.2', 'Exclusion Criteria', 'Patients meeting any of the following criteria are ineligible to participate in this study:', '1. Prior treatment with Prontosan solution or Prontosan gel on the wound(s)', '2. Infection in the wound(s)', '3. Cartilage exposure in the wound(s)', '14 November 2018', 'Page 28']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '4. Antibiotic therapy within 7 days prior to baseline (i.e., prior to first administration of', 'study treatment). Topical antibiotics not applied to the wound are acceptable.', '5. Current diagnosis of severe peripheral artery disease as indicated by clinical findings', '(i.e., no palpable pulse on both dorsal pedis and posterior tibial arteries of the affected', 'limb) or an Ankle Brachial Index of VI 0.5', '6. Presence of gangrene in the wound(s) or on the leg(s)', '7. Active (flare up) rheumatic or collagen vascular disease (including rheumatoid', 'arthritis, scleroderma, and systemic lupus erythematosus), psoriasis, sarcoidosis, or', 'other skin disease. These subjects are allowed to receive oral, inhaled, or parenteral', 'corticosteroids, immunosuppressive agents, or cytotoxic agents. Note: fibromyalgia is', 'acceptable.', '8. Osteomyelitis diagnosed by x-ray, bone biopsy, or other radiological procedure', 'within 90 days prior to the screening visit', '9. Active radiation therapy below the hip', '10. Subjects with medical conditions other than those identified in Exclusion Criteria 7', 'who are currently receiving or has received oral, or parenteral corticosteroids,', 'immunosuppressive agents, or cytotoxic agents within 30 days prior to baseline (i.e.,', 'prior to first administration of study treatment) or is anticipated to require such agents', 'during the course of the study', '11. Clinical laboratory values that may impair wound healing; for example, hemoglobin', '<10 g/dL, or HbAlc>12%', '12. Enrolled in any investigational drug or device study for any disease/indication within', '30 days prior to the screening visit', '13. Unable to comprehend or comply with study requirements, or inability to sign an', 'informed consent form (ICF)', '14. Allergic to any of the components in Prontosan solution or Prontosan gel', '15. Patients who, in the opinion of the Investigator, would not be suitable candidates for', 'this study or have some impediment to their ability to heal', '16. Preplanned surgery or procedures that would occur during the study (other than', 'deemed minor and clinically non-significant by the Investigator) or that would', 'interfere with the study', '17. Phase 4 pressure ulcer as defined by full-thickness skin and tissue loss with exposed', 'or directly palpable fascia, muscle, tendon, ligament, cartilage or bone in the ulcer.', 'Slough and/or eschar may be visible', '18. Severe secondary lymphedema as diagnosed by clinical findings in inferior members', '(e.g., legs)', '19. A diagnosis of malnutrition as determined by either a low BMI (<18.5 kg/m2), or on', 'the combined finding of weight loss together with reduced BMI (age-specific)', '14 November 2018', 'Page 29']\n\n###\n\n", "completion": "END"}